Pharmaceuticals, Biotechnology and Life Sciences
MIAMI–(BUSINESS WIRE)–#biotech–OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies. These products provide a u…
MIAMI–(BUSINESS WIRE)–#biotech–OrganaBio, LLC (“OrganaBio”) announces the launch of the HematoPAC™-HSC-CB CD34+ hematopoietic stem cell (HSC) product, designed to support development of HSC-based allogeneic cell therapies. These products provide a u…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have…
DUBLIN–(BUSINESS WIRE)–The “Hemophilia A – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Hemophilia A, historical …
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have…
DUBLIN–(BUSINESS WIRE)–The “Hemophilia A – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Hemophilia A, historical …
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have…
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is pleased to share that researchers at Northwestern University have…
DUBLIN–(BUSINESS WIRE)–The “Hemophilia A – Market Insights, Epidemiology, and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the Hemophilia A, historical …